Business Context and Reporting Period
Company: Drugs Made In America Acquisition Corp. (DMAA)
Filing Type: Form 8-K (Current Report)
Reporting Date: March 23, 2026
Context: The Company, a Cayman Islands-based special purpose acquisition company (SPAC), reported the entry into a material definitive agreement and the creation of a direct financial obligation to secure interim financing for a potential business combination.
Key Financial Metrics
Debt and Liquidity:
- Interim Loan Issued: $100,000 principal amount issued to BV Advisory Partners, LLC.
- Total Contemplated Financing: $500,000 aggregate commitment under the Definitive Interim Investment and Sponsor Transition Agreement.
- Tranche Schedule: Initial $100,000 received; second tranche of $200,000 due within 21 days; remainder available on an as-needed basis.
- Interest Rate: 0% (Non-interest bearing).
- Maturity: Six months from issuance date, unless earlier converted or credited.
Revenue, Profit, and Margins: The filing text does not provide a clear value for revenue, profit, cash flow, or margins as this is a current report regarding a specific transaction rather than a periodic financial statement.
Material Changes and Transaction Details
Convertible Note Terms:
- Conversion Option: Upon consummation of a Business Combination, the Investor may convert the outstanding principal into shares of the combined entity.
- Conversion Price: 35% discount to the market price of the shares at the time of conversion.
- Use of Proceeds: Accounting expenses, audit expenses, and other costs related to a Business Combination.
Sponsor Economics: The Company agreed to provide the Investor with not less than 40% of the economic benefit equivalent to sponsor-level economics.
Outlook, Risks, and Management Commentary
Target Opportunity: The Investor introduced a potential business combination target involving an enterprise technology platform focused on artificial intelligence, machine learning, quantum analytics, and cybersecurity solutions (consistent with Power Analytics Global Corporation).
Current Status: Preliminary due diligence has commenced. No letter of intent, term sheet, or definitive agreement has been executed as of the report date.
Risks and Contingencies:
- Transaction Uncertainty: There can be no assurance that a business combination will result from the current evaluation.
- Additional Funding: The Investor has the right, but not the obligation, to provide funding beyond the $500,000 commitment.
Investor Verification Checklist
- Verify the execution of the second tranche ($200,000) within the 21-day window.
- Monitor the progress of due diligence regarding the AI and cybersecurity target to assess the likelihood of a definitive agreement.
- Review the full text of the Definitive Interim Investment and Sponsor Transition Agreement (Exhibit 10.1) for additional covenants.
- Confirm the Company's cash runway given the stated use of proceeds for audit and accounting expenses.
- Assess the dilution impact of the 35% conversion discount should a business combination occur.